Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 92-96 , April 2002

Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide

  • Yusuf Menda

      Affiliations

    • Division of Nuclear Medicine, University of Iowa College of Medicine Iowa City, IA, USA
    • Veterans Affairs Medical Center, Iowa City, IA, USA
    • Corresponding Author InformationAddress reprint requests to Yusuf Menda, MD, 3858 JPP, 200 Hawkins Dr, University of Iowa Hospitals and Clinics, Iowa City, IA 52246 Copyright 2002, Elsevier Science (USA). All rights reserved.
    • ,
  • Daniel Kahn

      Affiliations

    • Division of Nuclear Medicine, University of Iowa College of Medicine Iowa City, IA, USA
    • Veterans Affairs Medical Center, Iowa City, IA, USA

References 

  1. Reubi JC, Krenning E, Lamberts SWJ, et al. In vitro detection of somatostatin receptors in human tumors. Metabolism. 1992;41:104–110
  2. Kwekkeboom DJ, Kho GS, Lamberts SW, et al. The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med. 1994;21:1106–1113
  3. Fujita T, Yamaji Y, Sato M, et al. Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci. 1994;55:1797–1806
  4. Virgolini I, Leimer M, Handmaker H, et al. Somatostatin receptor subtype specificity, and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58:1850–1859
  5. Reubi JC, Schaer JC, Laissue JA, et al. Somatostatin receptors and their subtypes in human tumors and peritumoral vessels. Metabolism. 1996;45:39–41
  6. Vallabhajosula S, Moyer B, Lister-James J, et al. Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med. 1996;37:1016–1022
  7. Lister-James J, McBride WJ, Moyer BR, et al. A structure-activityrelationship study of somatostatin receptor-binding peptides radiolabeled with Tc-99m. J Nucl Med. 1994;35:257P
  8. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatintype receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1999;115:224–232
  9. Blum J, Handmaker H, Lister-James J, et al. Neo Tect Solitary Pulmonary Nodule Study Group A multicenter trial with a somatostatin analog 99mTc Depreotide in the evaluation of solitary pulmonary nodules. Chest. 2000;117:1232–1238
  10. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA. 2001;285:914–924
  11. Kernstine KH, Kahn D, Menda Y, et al. A new technique for staging potentially-resectable lung cancer: Neo Tect Spect Tc-99m (NeoT), compared with F-18 FDG. In: American Society of Clinical Oncology Program/Proceedings. 20:2001;p. 339a
  12. Berkowitz M, Waxman AD. The utility of NeoTect in the evaluation of pulmonary malignancy. J Nucl Med. 2001;42:28P
  13. Menda Y, Kahn D, Bushnell DL, et al. Nonspecific mediastinal uptake of 99mTc depreotide (NeoTectTM). J Nucl Med. 2001;42:304P

PII: S0001-2998(02)80027-7

doi: 10.1053/snuc.2002.31564

Seminars in Nuclear Medicine
Volume 32, Issue 2 , Pages 92-96 , April 2002

Article Tools